2019
F195. NMDAR Antagonism via Ketamine Differentially Modulates Thalamic Versus Hippocampal Brain-Wide Functional Connectivity
Moujaes F, Schleifer C, Ji L, Adkinson B, Kolobaric A, Flynn M, Fineberg S, Krystal J, Repovs G, Cho Y, Santamauro N, Morgan P, Savic A, Murray J, Anticevic A. F195. NMDAR Antagonism via Ketamine Differentially Modulates Thalamic Versus Hippocampal Brain-Wide Functional Connectivity. Biological Psychiatry 2019, 85: s289. DOI: 10.1016/j.biopsych.2019.03.732.Peer-Reviewed Original Research
2017
423 NMDAR Antagonism via Ketamine Differentially Modulates Thalamic versus Hippocampal Functional Connectivity
Anticevic A, Schleifer C, Srihari V, Krystal J, Murray J, Repovs G, Xu G, Ji L, Cho Y, Santamauro N, Foss-Feig J, Yang G, Morgan P, Savic A. 423 NMDAR Antagonism via Ketamine Differentially Modulates Thalamic versus Hippocampal Functional Connectivity. Biological Psychiatry 2017, 81: s172-s173. DOI: 10.1016/j.biopsych.2017.02.907.Peer-Reviewed Original Research
2014
N-Methyl-D-Aspartate Receptor Antagonist Effects on Prefrontal Cortical Connectivity Better Model Early Than Chronic Schizophrenia
Anticevic A, Corlett PR, Cole MW, Savic A, Gancsos M, Tang Y, Repovs G, Murray JD, Driesen NR, Morgan PT, Xu K, Wang F, Krystal JH. N-Methyl-D-Aspartate Receptor Antagonist Effects on Prefrontal Cortical Connectivity Better Model Early Than Chronic Schizophrenia. Biological Psychiatry 2014, 77: 569-580. PMID: 25281999, DOI: 10.1016/j.biopsych.2014.07.022.Peer-Reviewed Original ResearchConceptsHealthy volunteersFunctional connectivityKetamine effectsChronic schizophreniaIllness progressionChronic illnessHigh riskRecent pharmacologic studiesReceptor antagonist effectsAspartate glutamate receptorsStages of schizophreniaCourse of schizophreniaGlutamate dysfunctionPharmacologic modelsPrefrontal cortex functionIllness stageNMDAR antagonistsFunctional dysconnectivityGlutamate receptorsPharmacologic studiesHealthy subjectsSchizophrenia onsetFunctional alterationsDevelopment of therapeuticsAntagonist effects
2013
Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
Driesen NR, McCarthy G, Bhagwagar Z, Bloch M, Calhoun V, D'Souza DC, Gueorguieva R, He G, Ramachandran R, Suckow RF, Anticevic A, Morgan PT, Krystal JH. Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans. Molecular Psychiatry 2013, 18: 1199-1204. PMID: 23337947, PMCID: PMC3646075, DOI: 10.1038/mp.2012.194.Peer-Reviewed Original ResearchConceptsFunctional connectivityNegative symptomsGamma-aminobutyric acid (GABA) neuronsNMDA receptor antagonist ketamineAspartate glutamate receptor antagonistContinuous ketamine infusionGlutamate receptor antagonistsNMDA-R antagonistsCortical functional connectivityNMDA-R antagonist ketamineSchizophrenia-like symptomsHealthy human subjectsNegative Syndrome ScaleBrain functional connectivityPrimary samplesRegion-specific mannerFunctional magnetic resonanceKetamine infusionReceptor antagonistPathological increaseSyndrome ScaleSymptomsPreclinical researchKetamineBrain oscillations